Arbutus Biopharma Corp (ABUS) — Long-term Investment Intensity
Arbutus Biopharma Corp (ABUS) has a Long-term Investment Intensity of 2.1% as of September 2024. Long-term investments of $2.96 Million represent 2.1% of total assets of $140.44 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check ABUS total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Arbutus Biopharma Corp Long-term Investment Intensity (2015–2023)
This chart shows how Arbutus Biopharma Corp's Long-term Investment Intensity has evolved across 5 annual periods from 2015 to 2023. As of September 2024, the intensity stands at 2.1%, reflecting long-term investments of $2.96 Million against total assets of $140.44 Million USD. Explore ABUS debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Arbutus Biopharma Corp (2015–2023)
The table below presents the year-by-year Long-term Investment Intensity for Arbutus Biopharma Corp from 2015 to 2023, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see Arbutus Biopharma Corp market capitalisation.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2023 | 4.4% | $6.28 Million | $144.40 Million | ▼ -14.8 pp |
| 2022 | 19.1% | $37.36 Million | $195.42 Million | ▲ +1.7 pp |
| 2021 | 17.5% | $35.69 Million | $204.49 Million | ▲ +7.7 pp |
| 2018 | 9.8% | $22.22 Million | $227.91 Million | ▲ +8.3 pp |
| 2015 | 1.4% | $10.07 Million | $712.29 Million | — |